<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602784</url>
  </required_header>
  <id_info>
    <org_study_id>IC41-201</org_study_id>
    <nct_id>NCT00602784</nct_id>
  </id_info>
  <brief_title>Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine</brief_title>
  <official_title>Double Blind, Randomized, Multicenter, Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine Together With Polyarginine, HCV Peptide Vaccine Alone, or Polyarginine Alone, in Patients With Chronic HCV Having Not Responded to or Relapsed From Primary Standard HCV Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives are

        1. to determine the immunological profile (CD4+, CD8+ cells, DTH) induced by immunization
           with HCV antigen peptide vaccine with polyarginine.

        2. to document virological (HCV-RNA) and biochemical (ALT) responses following immunization
           with HCV antigen peptide vaccine with polyarginine.

        3. to assess the safety of immunization with HCV antigen peptide vaccine with polyarginine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, randomized, parallel group, controlled, multicenter phase II study.

      60 patients will be enrolled and assigned to one of the 5 dose or control groups. Each study
      group will include 8 patients.

      Each patient will receive a total of 6 injections according to the dose of the assigned study
      group. The injections will be administered subcutaneously in the upper arm once every four
      weeks for 5 months, i.e. at days 1, 29, 57, 85, 113 and 141.

      The volume of each injection will be 0.5 ml in all groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological assays</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>IC41-B-01/02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peptide dose 0.00 mg, polyarginine dose 2.00 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC41-C-01/02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peptide dose: 5.00 mg, polyarginine dose: 0.00 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC41-G-01/02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peptide dose: 2.50 mg, polyarginine dose: 1.25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC41-H-01/02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peptide dose: 2.50 mg, polyarginine dose: 2.00 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC41-K-01/02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peptide dose: 5.00 mg, polyarginine dose: 2.00 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC41</intervention_name>
    <arm_group_label>IC41-B-01/02</arm_group_label>
    <arm_group_label>IC41-C-01/02</arm_group_label>
    <arm_group_label>IC41-G-01/02</arm_group_label>
    <arm_group_label>IC41-H-01/02</arm_group_label>
    <arm_group_label>IC41-K-01/02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic hepatitis C

          -  Non-response to or relapse from primary standard HCV therapy

          -  HLA A2 positive

          -  HCV-RNA positive

          -  HCV antibodies positive

          -  Liver biopsy within 30 months prior to inclusion

          -  Hematology and biochemistry laboratory results within the limits normally expected for
             the patient population (liver values maximal 5 times the upper limit of normal)

          -  Male and female

          -  From 18 to 65 years

          -  Written informed consent obtained prior to study entry

        Exclusion Criteria:

          -  Any degree of liver cirrhosis or fibrosis of Ishak score â‰¥ 4 (for grading table, see
             APPENDIX 2: The Ishak Modified Hepatic Activity Index (HAI))

          -  Any liver disease other than hepatitis C

          -  History of autoimmune disease

          -  Immunodeficiency including post-organ-transplantation

          -  HIV infection

          -  Immunosuppressive therapy

          -  Any acute infections within 4 weeks prior to inclusion

          -  History of severe hypersensitivity reactions, anaphylaxis or atopy

          -  Diabetes mellitus, severe cardiopulmonary disorders, history of malignancy in the past
             5 years

          -  Active or passive vaccination within 2 months prior to enrolment, and concomitant
             vaccination throughout the study period

          -  Pregnancy or lactation

          -  Unreliable contraception

          -  Alcohol consumption

          -  Drug abuse or addiction within 12 months prior to inclusion

          -  Participation in a methadone program

          -  Participation in another study within 1 month prior to enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erich Tauber, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

